Table 1 KRAS mutation incidence across aerodigestive malignancies
From: Drugging KRAS: current perspectives and state-of-art review
Aerodigestive malignancy | KRAS mutation incidence (%) | G12C (%) | G12D (%) | G12V (%) | G12X (%) | G13X (%) | Q61X (%) |
|---|---|---|---|---|---|---|---|
Pancreatic adenocarcinoma | 91 [173] | 1 | 39 | 31 | 91 | 2 | 7 |
Non-small cell lung cancer | 23 [174] | 41 | 12 | 22 | 88 | 5 | 2 |
Adenocarcinoma | 33 [175] | ||||||
Squamous cell carcinoma | 5 [176] | ||||||
Colorectal adenocarcinoma | 6.5 | 27.5 | 20 | 65 | 19 | 4.5 | |
Cholangiocarcinoma | 5 | 35 | 22 | 71 | 5 | 13 | |
Esophageal carcinoma | 6 | 25 | 19 | 53 | 19 | < 1 | |
Gastric adenocarcinoma | 9.8 [183] | < 1 | 26 | < 1 | 44 | 37 | 11 |